Jun 2026 (Q2 FY26) — Aug 12, 2026
Marex Group Q2 FY26 — Record Profit Quarter & Strong Structural Growth
Read the full callMarex Group earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Price
1Y: $30.58 on 17 Oct 2025 → $69.65. High $78.27 (4 Sept 2026), low $30.2 (30 Oct 2025).
Overview
Call summaries
Marex Group Q2 FY26 — Record Profit Quarter & Strong Structural Growth
Read the full callMarex Q1 FY26 — Record Performance Driven by Volatility and Structural Growth
Read the full callMarex Q4 FY25 — Record Profitability Driven by Broad-Based Strength and Strategic Acquisitions
Read the full callEvery analysed call
Financials
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total liabilities | 15,066 | 16,836 | 23,336 | 33,412 |
| Fixed assets | 12 | 17 | 21 | 34 |
| Total assets | 15,744 | 17,612 | 24,313 | 34,675 |
| Line item | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Cash from operations | 226 | 735 | 1,164 | 668 |
| Cash from investing | -46 | -98 | -35 | -264 |
| Cash from financing | 27 | -73 | -37 | -124 |
| Capital expenditure | -4 | -9 | -12 | -13 |
| Free cash flow | 222 | 726 | 1,152 | 654 |
62 filings between Apr 1, 2026 and Oct 12, 2026.
Purchases
None
No insider bought shares.
Sales
$17.18M
39 sales by 5 insiders
95% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Tonucci Paolo | — | $7.30M | Oct 12, 2026 |
| Lowitt Ian T | — | $4.71M | Jul 13, 2026 |
| Van Den Born Simon | — | $3.44M | Oct 12, 2026 |
| Texier Thomas | — | $1.48M | Jun 1, 2026 |
| Irvin Rob | — | $262.5K | Aug 14, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 1,160 | $84.3K |
| Oct 12, 2026 | Van Den Born Simon President | Sale 10b5-1 plan | 14,012 | $1.01M |
| Oct 12, 2026 | Van Den Born Simon President | Sale 10b5-1 plan | 1,260 | $91.5K |
| Oct 12, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 15,506 | $1.12M |
| Sep 14, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 2,952 | $210.6K |
| Sep 14, 2026 | Van Den Born Simon President | Sale 10b5-1 plan | 2,655 | $189.5K |
| Sep 14, 2026 | Van Den Born Simon President | Sale 10b5-1 plan | 12,616 | $892.8K |
| Sep 14, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 13,714 | $970.5K |
| Sep 7, 2026 | Lowitt Ian T Chief Executive Officer | Tax withheld | 36,587 | $2.86M |
| Sep 7, 2026 | Tonucci Paolo See Remarks | Tax withheld | 18,293 | $1.43M |
| Sep 7, 2026 | Van Den Born Simon President | Tax withheld | 13,215 | $1.03M |
| Sep 7, 2026 | Jethwa Nilesh CEO, Marex Solutions | Tax withheld | 31,567 | $2.47M |
| Aug 19, 2026 | Lowitt Ian T Chief Executive Officer | Award | 77,843 | $0 |
| Aug 19, 2026 | Van Den Born Simon President | Award | 33,582 | $0 |
| Aug 19, 2026 | Jethwa Nilesh CEO, Marex Solutions | Award | 67,163 | $0 |
| Aug 19, 2026 | Tonucci Paolo See Remarks | Award | 38,921 | $0 |
| Aug 14, 2026 | Irvin Rob Chief Financial Officer | Sale | 200 | $14.4K |
| Aug 14, 2026 | Irvin Rob Chief Financial Officer | Sale | 3,500 | $248.2K |
| Aug 10, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 3,963 | $244.2K |
| Aug 10, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 12,250 | $742.8K |
| Aug 10, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 455 | $28.3K |
| Jul 13, 2026 | Lowitt Ian T Chief Executive Officer | Sale 10b5-1 plan | 8,957 | $581.3K |
| Jul 13, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 11,850 | $761.1K |
| Jul 13, 2026 | Lowitt Ian T Chief Executive Officer | Sale 10b5-1 plan | 27,398 | $1.76M |
| Jul 13, 2026 | Lowitt Ian T Chief Executive Officer | Sale 10b5-1 plan | 787 | $51.8K |
| Jul 13, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 232 | $15.2K |
| Jul 13, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 4,584 | $297.3K |
| Jun 15, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 809 | $51.0K |
| Jun 15, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 14,199 | $887.5K |
| Jun 15, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 1,658 | $102.4K |
| Jun 12, 2026 | Lowitt Ian T Chief Executive Officer | Sale 10b5-1 plan | 32,813 | $2.04M |
| Jun 12, 2026 | Lowitt Ian T Chief Executive Officer | Sale 10b5-1 plan | 4,330 | $272.5K |
| Jun 9, 2026 | Pietrowicz John W. Director | Award | 2,070 | $0 |
| Jun 9, 2026 | Assi Georges Director | Award | 2,070 | $0 |
| Jun 9, 2026 | Schweinitz Konstantin Graf von Director | Award | 2,070 | $0 |
| Jun 9, 2026 | Ing Sarah Director | Award | 2,070 | $0 |
| Jun 9, 2026 | Pickering Robert Mark Director | Award | 2,070 | $0 |
| Jun 9, 2026 | Myers Linda Kristine Director | Award | 2,070 | $0 |
| Jun 1, 2026 | Texier Thomas Group Head of Clearing | Sale 10b5-1 plan | 1,303 | $69.3K |
| Jun 1, 2026 | Texier Thomas Group Head of Clearing | Sale 10b5-1 plan | 269 | $14.5K |
| Jun 1, 2026 | Myers Linda Kristine Director | Tax withheld | 1,115 | $59.0K |
| Jun 1, 2026 | Ing Sarah Director | Tax withheld | 1,310 | $69.4K |
| Jun 1, 2026 | Pietrowicz John W. Director | Tax withheld | 558 | $29.5K |
| May 22, 2026 | Jethwa Nilesh CEO, Marex Solutions | Tax withheld | 39,661 | $2.16M |
| May 22, 2026 | Texier Thomas Group Head of Clearing | Tax withheld | 19,640 | $1.07M |
| May 22, 2026 | Lowitt Ian T Chief Executive Officer | Tax withheld | 39,478 | $2.15M |
| May 22, 2026 | Irvin Rob Chief Financial Officer | Tax withheld | 3,358 | $182.8K |
| May 22, 2026 | Van Den Born Simon President | Tax withheld | 43,712 | $2.38M |
| May 22, 2026 | Tonucci Paolo See Remarks | Tax withheld | 31,080 | $1.69M |
| May 11, 2026 | Tonucci Paolo See Remarks | Sale 10b5-1 plan | 5,734 | $322.9K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow Marex Group plc and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading